Skip to content

Psoas Density in Colorectal Cancer

Evaluating the Association Between Psoas Density Measurement on Preoperative CT Imaging and Postoperative Outcomes

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04198025
Enrollment
1000
Registered
2019-12-13
Start date
2020-01-01
Completion date
2020-12-01
Last updated
2019-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer of Colon

Keywords

psoas muscle density, frailty

Brief summary

Colorectal cancer (CRC) is the 3rd most common cancer worldwide. In the UK, CRC is the 4th most common cancer accounting for 12% of cancers diagnosed each year with approximately 41,300 new cases diagnosed in 2014. Surgery remains the only treatment option that can reliably achieve cure from colorectal cancer and thus nearly 20,000 major bowel resections are performed for this yearly in the UK. Surgery for these cancers however carries risk of major complications and potentially death. Selecting appropriate patients for surgery remains a challenge to cancer teams. Risk factors exist for complications after surgery for CRC, many of which can be assessed and discussed with the patient prior to surgery, so that any decision to operate is with fully informed consent from the patient. Increasing attention is being paid to a patient's frailty or fitness as one of these risk factors. Our centre has previously shown that measuring the cross-sectional area of the psoas muscle (a large muscle near the spine) from preoperative imaging could predict major complications in colorectal cancer patients (Jones 2015), however specialist software and patient height is required to make this calculation. More recently we have demonstrated that the measurement of the psoas muscle density on preoperative imaging (i.e. routine CT scans that all patients have before surgery to plan treatment), may potentially be useful to predict which patients are at most risk of a major complication (Herrod 2019). If this finding holds true when tested on a larger scale, it could be used to help surgical teams make the decision on whether to offer surgical resection, what kind of operations to perform, how to best support individuals undergoing operation and to ensure that the patient has the most information available to decide what risk they are at by having major surgery.

Interventions

None listed

Sponsors

University of Nottingham
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patient criteria: * Having a major colorectal resection for the treatment of cancer * Elective or emergency surgery * Adults, defined as age ≥18 years of age (no maximum limit) * Had a preoperative CT scan of the abdomen with contrast (portal venous phase) * Operation performed between 31st Aug 2013 - 31st Aug 2019

Exclusion criteria

* Not having a preoperative CT scan with contrast

Design outcomes

Primary

MeasureTime frameDescription
Number of post operative complications (Clavien-Dindo grade 3-4) during inpatient hospital stay.Through study completion, an average of 10 days.Recorded post operative complications requiring intervention during post operative stay until initial discharge from hospital.

Secondary

MeasureTime frameDescription
Post operative length of stayThrough study completion, usually between 6-10 days.Number of days
MortalityUp to 5 year follow up from operationRecorded patient death
Post operative complications beyond hospital discharge.From hospital discharge to record review (i.e. 30 days, 90 days, 2 - 5 year follow up).Recorded post operative complications (including re-operation or recurrence) until discharge from surgical clinic or date of record review.

Countries

United Kingdom

Contacts

Primary ContactJonathan N Lund, MD
jon.lund@nottingham.ac.uk01332 340131
Backup ContactJames EM Blackwell, PhD BMBS
james.blackwell@nhs.net01332 340131

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026